Patents by Inventor Michael B. Roof

Michael B. Roof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10702601
    Abstract: The present invention relates to immunogenic compositions, wherein the immunogenic compositions include a recombinant spike antigen porcine epidemic diarrhea virus (PEDV). The immunogenic compositions commonly include an oil-in-water emulsion as an adjuvant. Methods for producing the immunogenic compositions and the recombinant PEDV spike antigen are also provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 7, 2020
    Inventors: Luis Alejandro Hernandez, Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria
  • Patent number: 10668144
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 2, 2020
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Patent number: 10624963
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: April 21, 2020
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 10568955
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: February 25, 2020
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10545148
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: January 28, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Publication number: 20190154688
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 23, 2019
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Publication number: 20190134180
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 9, 2019
    Inventors: Kim BURGARD, Jeremy KROLL, Sarah M. LAYTON, Volker OHLINGER, Francois-Xavier ORVEILLON, Stefan PESCH, Michael Dennis PIONTKOWSKI, Michael B. ROOF, Philip UTLEY, Eric Martin VAUGHN
  • Patent number: 10168330
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 1, 2019
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Publication number: 20180236057
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10039821
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Publication number: 20180207260
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Luis Alejandro HERNANDEZ, Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • Publication number: 20180169213
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Application
    Filed: January 31, 2018
    Publication date: June 21, 2018
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9987349
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9950061
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria
  • Patent number: 9925256
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9925255
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9833507
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 5, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Patent number: 9827306
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Publication number: 20170253908
    Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 7, 2017
    Inventors: Marc Allan Eichmeyer, Michael B. Roof, Merrill Lynn Schaeffer, Eric Martin Vaughn, Kun Yang, Jeremy Richard Rush, Daniel John Murfin
  • Patent number: 9669087
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 6, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer